Terms: = Liver cancer AND LRP1B, ENSG00000168702, 53353, Q9NZR2, LRPDIT, LRP-DIT AND Treatment
5 results:
1. Preliminary radiogenomic study of hepatitis B virus-related hepatocellular carcinoma: associations between MRI features and mutations.
Gao S; Wang F; Sun W; Qian X; Ji Y; Cheng Y; Wang X; Liu L; Sheng R; Zeng M
Per Med; 2023 May; 20(3):215-225. PubMed ID: 37199498
[TBL] [Abstract] [Full Text] [Related]
2. A lipid metabolism-based prognostic risk model for HBV-related hepatocellular carcinoma.
Zhou L; Xia S; Liu Y; Ji Q; Li L; Gao X; Guo X; Yi X; Chen F
Lipids Health Dis; 2023 Apr; 22(1):46. PubMed ID: 37004044
[TBL] [Abstract] [Full Text] [Related]
3. Profound tumor response to combined CTLA-4 and PD-1 inhibition in systemic fourth line therapy observed in a patient with hepatocellular carcinoma harboring SETD2 and lrp1b mutations.
Reiter FP; Rau M; Kunzmann V; Kickuth R; Klein I; Neumann O; Stenzinger A; Schirmacher P; Geier A
Z Gastroenterol; 2023 Jan; 61(1):71-75. PubMed ID: 36379463
[TBL] [Abstract] [Full Text] [Related]
4. Identification of driver genes and target drugs-related genes in liver cancer based on targeted next generation sequencing.
Cui Y; Sun L; Wang H; Zhang Z; Dai H; Liu P
Neoplasma; 2022 Jan; 69(1):95-102. PubMed ID: 34704453
[TBL] [Abstract] [Full Text] [Related]
5. The combination of camrelizumab and apatinib obtained ongoing partial remission for a patient with osimertinib-resistant non-small cell lung cancer: case report.
Cong X; Chen J; Zheng W
Ann Palliat Med; 2021 Mar; 10(3):3469-3474. PubMed ID: 33040541
[TBL] [Abstract] [Full Text] [Related]
